Reanalysis of a trial of LipiGesic M (PuraMed Bioscience) suggests treatment is effective for Migraine

A reanalysis of clinical trial results of homeopathic formulation, LipiGesic M (feverfew and ginger), from PuraMed Bioscience, confirms that the Migraine medication can provide effective relief. The original double-blind, placebo-controlled clinical trial for LipiGesic M, completed in 2010 and published in the July 2011 issue of Headache: The Journal of Head and Face Pain, concluded that 64 percent of patients who used LipiGesic M found relief. In this study, 60 subjects treated 208 evaluable attacks of migraine over a 1-month period; 45 subjects treated 163 attacks with sublingual feverfew/ginger and 15 subjects treated 58 attacks with a sublingual placebo preparation.

Following criticism of the original study, the reanalysis finds that "irrespective of design-type employed, the efficacy of sublingual feverfew/ginger (LipiGesic M) appears robust..." The authors suggest that given LipiGesic M's lower cost, its OTC availability, its unlikelihood to cause rebound headache, and its compatibility with other treatment options, it has some advantages in acute Migraine treatment. See: "Sublingual Feverfew/Ginger (LipiGesic M) Reanalysis of Data." Roger Cady MD et al. Headache: The Journal of Head and Face Pain, Volume 53, Issue 2, pages 384�386, February 2013 DOI: 10.1111/j.1526-4610.2012.02282.x